A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL

  检 索： 期刊名称 ISSN         高级检索

期刊名称：ARTIFICIAL CELLS BLOOD SUBSTITUTES AND BIOTECHNOLOGY ISSN： 1073-1199 版本： SCI-CDE 出版频率： Bimonthly 出版社： TAYLOR & FRANCIS INC, 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, USA, PA, 19106   出版社网址： www.informaworld.com/1073-1199 期刊网址： www.informaworld.com/1073-1199 影响因子： 0.932(2008) 主题范畴： MATERIALS SCIENCE, BIOMATERIALS;    ENGINEERING, BIOMEDICAL;    BIOTECHNOLOGY & APPLIED MICROBIOLOGY 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Artificial Cells, Blood Substitutes, and Biotechnology covers research and application on four structural levels: molecules, cells, tissues and organs. High quality papers are considered, with emphasis on the following topics: 路                 artificial cells 路                 blood substitutes 路                 nanomedicine and nanobiotechnology 路                 tissue engineering 路                 stem cells 路                 bioencapsulation 路                 cell therapy and gene therapy 路                 drug delivery 路                 other biotechnological approaches The addition of biotechnology, nanotechnology and molecular biology to polymer chemistry, engineering and medicine has revolutionised this field resulting in rapid developments. The journal is organised in a form to emphasise this modern and futuristic approach. The journal aims to provide the academic and industrial research communities with an integrated approach to biotechnology, and in particular nanotechnology and its applications in medicine. Abstracting & Indexing Academic Search Complete, Biochemistry and Biophysics Citation Index, Biological Abstracts, Biomedical Reference Collection: Comprehensive, BIOSIS Full Coverage Shared, BIOSIS Previews, Biotechnology Abstracts, Biotechnology Citation Index, COMPENDEX, EMBASE, EMBIOLOGY, Journal Citation Reports/Science Edition, Materials Science Citation Index, PubMed/MedLine, Science Citation Index, SciSearch, SCOPUS, SIIC. Instructions to Authors Artificial Cells, Blood Substitutes, and Biotechnology considers all manuscripts on the strict condition that they have been submitted only to Artificial Cells, Blood Substitutes, and Biotechnology, that they have not been published already, nor are they under consideration for publication or in press elsewhere. Authors will be asked to confirm this at the point of submission. Authors who fail to adhere to this condition will be charged with all costs that the publisher incurs and their papers will not be published. Original research article contributions to Artificial Cells, Blood Substitutes, and Biotechnology must report original research. Review papers on topical areas are also invited. Research papers and review papers will be subjected to peer review by referees. The following guidelines apply: i. For all manuscripts non-discriminatory language is mandatory. Sexist or racist terms should not be used. ii. Each paper should have two to six keywords. iii. Papers are accepted only in English. iv. All the authors of a paper should include their full names, affiliations, postal addresses, telephone and fax numbers and email addresses on the title page of manuscripts. v. Abstracts of 100-150 words are required for all papers submitted and should precede the text of a paper. vi. Manuscripts should be compiled in the following order: title page; abstract; keywords; main text; acknowledgments; declaration of interest statement; appendixes (as appropriate); references; table(s) with caption(s) (on individual pages); figure caption(s) (as a list). vii. Section headings should be concise and numbered sequentially, using a decimal system for subsections. ix. For information on submitting animations, movie files and sound files or any additional information including indexes and calendars please click here. x. Figures must be submitted as digital files, but care and attention to these guidelines are essential as importing graphics packages can be problematic. <!--[if !supportLists]-->Figures must be saved individually and separate to text. Please do not embed figures in the main text file. <!--[if !supportLists]-->Figures should be produced as near to the finished size as possible. <!--[if !supportLists]-->All figures must be numbered in the order in which they appear in the paper (e.g. figure 1, figure 2). In multi-part figures, each part should be labelled (e.g. figure 1(a), figure 1(b)). <!--[if !supportLists]-->Legends or captions for figures should be listed on a separate page, double spaced. <!--[if !supportLists]-->Files should be saved preferably as one of the following formats: TIFF (tagged image file format), PostScript or EPS (encapsulated PostScript), JPG, PSD (Photoshop document), and should contain all the necessary font information and the source file of the application (e.g. CorelDraw/Mac, CorelDraw/PC and others).      xi. When using a word which is or is asserted to be a proprietary term or trade mark authors must use the symbol 庐 or TM or alternatively a footnote can be inserted using the wording below: This article includes a word that is or is asserted to be a proprietary term or trade mark. Its inclusion does not imply it has acquired for legal purposes a non-proprietary or general significance, nor is any other judgement implied concerning its legal status. 5. Ethics and Consent When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 1983. Do not use patients' names, initials, or hospital numbers, especially in illustrative material. Papers including animal experiments or clinical trials must be conducted with approval by the local animal care or human subject committees, respectively. Identifying information should not be published in written descriptions, photographs, and pedigrees, unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that the patient be shown the manuscript to be published. 6. Disclosure of Potential Conflicts of Interest It is the sole responsibility of authors to disclose any affiliation with any organisation with a financial interest, direct or indirect, in the subject matter or materials discussed in the manuscript (such as consultancies, employment, expert testimony, honoraria, speakers' bureaus, retainers, stock options or ownership) that may affect the conduct or reporting of the work submitted. If uncertain as to what might be considered a potential conflict of interest, authors should err on the side of full disclosure. Information about potential conflict of interest should be clearly stated at the point of submission (for example in a cover letter, or where available within the appropriate field on the Journal's ScholarOne Manuscripts site). This may be made available to reviewers and may be published with the manuscript at the discretion of the Editors. 7. Disclosure of Sources of funding All sources of funding for research are to be explicitly stated, at the point of submission. This may be published with the manuscript at the discretion of the Editors. 8. Authorship Contributions Contributions must be substantial in order to warrant authorship. Each author should have participated sufficiently in the work to take public responsibility for the content. All other contributors should be listed as acknowledgements. <!--[if !supportLineBreakNewLine]--> <!--[endif]--> 9. Colour and Page Charges Any figure submitted as a colour original will appear in colour in the Journal's online edition free of charge and can be downloaded. Paper copy colour reproduction will only be considered on condition that authors contribute to the associated costs. The charges are 拢500/US$1030 for the first colour page and 拢250/US$515 for each subsequent colour page. There are no charges for non-colour pages. 10. Proofs The Editor reserves the right to proceed to press without submitting page proofs to the author. However, usual practice will involve corresponding authors receiving email notification with a password and Web address from which to download a PDF. Hard copies of proofs will not be mailed. To avoid delays in publication, corrections to proofs must be returned within 48 hours, by electronic transmittal, fax or mail. Authors will be charged for excessive correction at this stage of production. If authors do not return page proofs promptly, the Editor reserves the choice to either delay publication to a subsequent issue or to proceed to press without author corrections. 11. Offprints and Reprints Corresponding authors will receive an email providing a link to access a free copy of their article online. Reprints of articles published in this journal can be purchased through Rightslink庐 when proofs are received. For further information on reprints please click here. 12. Copyright It is a condition of publication that authors assign copyright or license the publication rights in their articles, including abstracts, to Informa UK Ltd. This enables us to ensure full copyright protection and to disseminate the article, and the Journal, to the widest possible readership in print and electronic formats as appropriate. Authors may, of course, use the article elsewhere after publication without prior permission from Informa UK Ltd., provided that acknowledgement is given to the Journal as the original source of publication, and that Informa Healthcare is notified so that our records show that its use is properly authorised. Authors retain a number of other rights under the Informa UK Ltd. rights policies documents. Authors are themselves responsible for obtaining permission to reproduce copyright material from other sources. A copyright agreement form can be downloaded by corresponding authors of accepted manuscripts with proofs. This should be signed and returned to Informa Healthcare. 13. NIH Public Access Policy In consideration of the National Institutes of Health (NIH) Public Access Policy, Informa Healthcare acknowledges that the broad and open dissemination of NIH-funded research results may benefit future scientific and medical research. Because we value the current and future contributions our journals make to the scientific body of knowledge, we have made certain that our policies accommodate those authors who wish to submit to PubMed Central. Informa Healthcare's position with respect to public access to NIH-funded work published in Informa Healthcare journals is as follows: <!--[if !supportLists]--><!--[endif]-->Informa Healthcare will deposit funded work to PubMed Central/UK PubMed Central for public access posting 12 months (NIH) or 6 months (Wellcome Trust) after final publication in electronic form. <!--[if !supportLists]-->鈥淔unded work鈥?shall be defined as the final, peer-reviewed manuscript that is accepted by the Editor in Chief of the journal. This manuscript must not be altered by Publisher's copyediting and typesetting services. <!--[if !supportLists]-->This embargo period begins the day the work is published online at www.informaworld.com. 14. Contacting the Publisher Artificial Cells, Blood Substitutes, and Biotechnology Informa Healthcare 5th Floor Telephone House 69-77 Paul Street London EC2A 4LQ, UK Tel: (+44) 207 017 6903 Fax: (+44) 207 017 6914 Email (Please include the Journal name in all correspondence.) Editorial Board Editor-in-Chief Thomas M. S. Chang, O.C., M.D., C.M., Ph.D., FRCP(C), FRS(C) Director, Artificial Cells and Organs Research Centre, Emeritus Professor of Physiology, Medicine and Biomedical Engineering Faculty of Medicine, McGill University 3655 Drummond Street, Room 1006 Montreal, Quebec, Canada, H3G 1Y6 Artcell.med@mcgill.ca